Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy

Initial therapy of multiple myeloma with lenalidomide-based regimens can compromise stem cell collection, which can be overcome with the addition of plerixafor. Plerixafor is typically given subcutaneously (SQ), with collection approximately 11 hours later for maximum yield. Intravenous (IV) adminis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kumar, Shaji K., Mikhael, Joseph, LaPlant, Betsy, Lacy, Martha Q., Buadi, Francis K., Dingli, David, Gertz, Morie A., Laumann, Kristina, Miceli, Teresa, Mahlman, Marcia, Bergsagel, Leif P., Hayman, Suzanne R., Reeder, Craig, Stewart, A. Keith, Dispenzieri, Angela, Gastineau, Dennis A., Winters, Jeffrey L
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3946357/
https://ncbi.nlm.nih.gov/pubmed/24185588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2013.175
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge